I

Invivyd Inc
NASDAQ:IVVD

Watchlist Manager
Invivyd Inc
NASDAQ:IVVD
Watchlist
Price: 2.32 USD -2.52% Market Closed
Market Cap: 642.8m USD

Relative Value

The Relative Value of one IVVD stock under the Base Case scenario is hidden USD. Compared to the current market price of 2.32 USD, Invivyd Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IVVD Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
12
vs Industry
51
Median 3Y
0
Median 5Y
0
Industry
7.9
Forward
12.4
vs History
vs Industry
Median 3Y
-2.2
Median 5Y
-2.6
Industry
23.7
Forward
-5.6
vs History
vs Industry
Median 3Y
-2.2
Median 5Y
-2.8
Industry
22
vs History
vs Industry
Median 3Y
-2.2
Median 5Y
-2.8
Industry
23.8
vs History
11
vs Industry
59
Median 3Y
2.8
Median 5Y
2.8
Industry
3.3
vs History
11
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.3
Forward
10.8
vs History
11
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
vs History
vs Industry
31
Median 3Y
-1
Median 5Y
-1.4
Industry
6.4
Forward
-9.8
vs History
vs Industry
29
Median 3Y
-1
Median 5Y
-1.4
Industry
7
Forward
-8.7
vs History
vs Industry
32
Median 3Y
-1
Median 5Y
-1.5
Industry
8.3
vs History
vs Industry
28
Median 3Y
-1
Median 5Y
-1.5
Industry
6.5
vs History
37
vs Industry
66
Median 3Y
7
Median 5Y
7.7
Industry
5.7

Multiples Across Competitors

IVVD Competitors Multiples
Invivyd Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Invivyd Inc
NASDAQ:IVVD
642.8m USD 12.8 -10.7 -9 -9
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 809 907.8 -160 693.5 -195 133.1 -192 906.4
US
Abbvie Inc
NYSE:ABBV
400.7B USD 6.7 170.6 16.5 23.4
US
Amgen Inc
NASDAQ:AMGN
172.3B USD 4.8 24.6 17.8 17.8
US
Gilead Sciences Inc
NASDAQ:GILD
149.8B USD 5.1 18.5 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.6B USD 9.8 31.1 22.9 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 083.7 -531.7 -579 -563.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD 5.6 17.3 16.5 18.7
AU
CSL Ltd
ASX:CSL
86.8B AUD 3.7 19.2 12.9 16.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52B USD 16.2 1 194.7 156.9 190.3
NL
argenx SE
XBRU:ARGX
42.9B EUR 14 32.9 56.5 58.1
P/S Multiple
Revenue Growth P/S to Growth
US
I
Invivyd Inc
NASDAQ:IVVD
Average P/S: 3 073 824.6
12.8
92%
0.1
FR
Pharnext SCA
OTC:PNEXF
33 809 907.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.8
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 083.7
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.2
46%
0.4
NL
argenx SE
XBRU:ARGX
14
49%
0.3
P/E Multiple
Earnings Growth PEG
US
I
Invivyd Inc
NASDAQ:IVVD
Average P/E: 188.6
Negative Multiple: -10.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 693.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.6
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.5
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.1
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
9%
1.9
AU
CSL Ltd
ASX:CSL
19.2
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 194.7
N/A N/A
NL
argenx SE
XBRU:ARGX
32.9
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
I
Invivyd Inc
NASDAQ:IVVD
Average EV/EBITDA: 39
Negative Multiple: -9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 133.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.8
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
11%
1.5
AU
CSL Ltd
ASX:CSL
12.9
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
156.9
N/A N/A
NL
argenx SE
XBRU:ARGX
56.5
839%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
I
Invivyd Inc
NASDAQ:IVVD
Average EV/EBIT: 45.1
Negative Multiple: -9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 906.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.8
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.7
13%
1.4
AU
CSL Ltd
ASX:CSL
16.1
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
190.3
N/A N/A
NL
argenx SE
XBRU:ARGX
58.1
N/A N/A